{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:20:42Z","timestamp":1790256042936,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T00:00:00Z","timestamp":1549497600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00228-019-02641-0","type":"journal-article","created":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T21:55:56Z","timestamp":1549490156000},"page":"769-776","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The evidence-based choice for antipsychotics in children and adolescents should be guaranteed"],"prefix":"10.1007","volume":"75","author":[{"given":"Daria","family":"Putignano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Clavenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Reale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3997-3726","authenticated-orcid":false,"given":"Maurizio","family":"Bonati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,7]]},"reference":[{"key":"2641_CR1","unstructured":"EMA. Regulation (EC) No 1901\/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for pediatric use and amending Regulation (EEC) No 1768\/92, Directive 2001\/20\/EC, Directive 2001\/83\/EC and Regulation (EC) No 726\/2004. \n                    https:\/\/ec.europa.eu\/health\/sites\/health\/files\/files\/eudralex\/vol1\/reg_2006_1901\/reg_2006_1901_en.pdf\n                    \n                   (Access 26 Sept 2018)."},{"issue":"6","key":"2641_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/archdischild-2017-313309","volume":"103","author":"S Nordenmalm","year":"2018","unstructured":"Nordenmalm S, Tomasi P, Pallidis C (2018) More medicines for children: impact of the EU paediatricpediatric regulation. Arch Dis Child 103(6):557\u2013564. \n                    https:\/\/doi.org\/10.1136\/archdischild-2017-313309","journal-title":"Arch Dis Child"},{"key":"2641_CR3","unstructured":"European Medicines Agency and its Pediatric Committee. 10-year report to the European Commission general report on the experience acquired as a result of the application of the pediatric Regulation. 27 October 2016 EMA\/231225\/2015 human medicines Research and Development support division. \n                    https:\/\/ec.europa.eu\/health\/sites\/health\/files\/files\/paediatricpediatrics\/2016_pc_report_2017\/ema_10_year_report_for_consultation.pdf\n                    \n                   (Access 26 Sept 2018)"},{"issue":"9","key":"2641_CR4","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s00431-005-1698-8","volume":"164","author":"C Pandolfini","year":"2005","unstructured":"Pandolfini C, Bonati M (2005) A literature review on off-label drug use in children. Eur J Pediatr 164(9):552\u2013558. \n                    https:\/\/doi.org\/10.1007\/s00431-005-1698-8","journal-title":"Eur J Pediatr"},{"issue":"1","key":"2641_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1136\/archdischild-2016-311527","volume":"102","author":"M Bonati","year":"2017","unstructured":"Bonati M, Jacqz-Aigrain E, Choonara I (2017) Licensed medicines, off-label use or evidence-based. Which is most important? Arch Dis Child 102(1):53\u201354. \n                    https:\/\/doi.org\/10.1136\/archdischild-2016-311527","journal-title":"Arch Dis Child"},{"issue":"3","key":"2641_CR6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1542\/peds.2013-4060","volume":"133","author":"DA Frattarelli","year":"2014","unstructured":"Frattarelli DA, Galinkin JL, Green TP, Johnson TD, Neville KA, Paul IM, Van Den Anker JN, American Academy of Pediatrics, Committee on Drugs (2014) Off-label use of drugs in children. Pediatrics 133(3):563\u2013567. \n                    https:\/\/doi.org\/10.1542\/peds.2013-4060","journal-title":"Pediatrics"},{"issue":"5","key":"2641_CR7","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/JCP.0000000000000559","volume":"36","author":"JV Bra\u00fcner","year":"2016","unstructured":"Bra\u00fcner JV, Johansen LM, Roesbjerg T, Pagsberg AK (2016) Off-label prescription of psychopharmacological drugs in child and adolescent psychiatry. J Clin Psychopharmacol 36(5):500\u2013507. \n                    https:\/\/doi.org\/10.1097\/JCP.0000000000000559","journal-title":"J Clin Psychopharmacol"},{"issue":"23","key":"2641_CR8","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.2174\/1381612821666150619092903","volume":"21","author":"L Carton","year":"2015","unstructured":"Carton L, Cottencin O, Lapeyre-Mestre M, Geoffroy PA, Favre J, Simon N, Bordet R, Rolland B (2015) Off-label prescribing of antipsychotics in adults, children and elderly individuals: a systematic review of recent prescription trends. Curr Pharm Des 21(23):3280\u20133297","journal-title":"Curr Pharm Des"},{"issue":"8","key":"2641_CR9","first-page":"428","volume":"34","author":"CL Ventola","year":"2009","unstructured":"Ventola CL (2009) Off-label drug information: regulation, distribution, evaluation, and related controversies. PT 34(8):428\u2013440","journal-title":"PT"},{"key":"2641_CR10","unstructured":"General Medical Council (2018) Good practice in prescribing and managing medicines and devices \n                    https:\/\/www.gmc-uk.org\/ethical-guidance\/ethical-guidance-for-doctors\/prescribing-and-managing-medicines-and-devices\n                    \n                   (Access 26 Sept 2018)"},{"issue":"8","key":"2641_CR11","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.euroneuro.2010.07.002","volume":"21","author":"D Fraguas","year":"2011","unstructured":"Fraguas D, Correll CU, Merch\u00e1n-Naranjo J, Rapado-Castro M, Parellada M, Moreno C, Arango C (2011) Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol 21(8):621\u2013645. \n                    https:\/\/doi.org\/10.1016\/j.euroneuro.2010.07.002","journal-title":"Eur Neuropsychopharmacol"},{"issue":"10","key":"2641_CR12","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.euroneuro.2015.06.009","volume":"25","author":"AM Persico","year":"2015","unstructured":"Persico AM, Arango C, Buitelaar JK, Correll CU, Glennon JC, Hoekstra PJ, Moreno C, Vitiello B, Vorstman J, Zuddas A, European Child and Adolescent Clinical Psychopharmacology Network (2015) Unmet needs in pediatric psychopharmacology: present scenario and future perspectives. Eur Neuropsychopharmacol 25(10):1513\u20131531. \n                    https:\/\/doi.org\/10.1016\/j.euroneuro.2015.06.009","journal-title":"Eur Neuropsychopharmacol"},{"issue":"8","key":"2641_CR13","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.euroneuro.2011.04.001","volume":"21","author":"A Zuddas","year":"2011","unstructured":"Zuddas A, Zanni R, Usala T (2011) Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsychopharmacol 21(8):600\u2013620. \n                    https:\/\/doi.org\/10.1016\/j.euroneuro.2011.04.001","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"2641_CR14","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1176\/appi.ps.201500482","volume":"68","author":"PL O'Brien","year":"2017","unstructured":"O'Brien PL, Cummings N, Mark TL (2017) Off-label prescribing of psychotropic medication, 2005-2013: an examination of potential influences. Psychiatr Serv 68(6):549\u2013558. \n                    https:\/\/doi.org\/10.1176\/appi.ps.201500482","journal-title":"Psychiatr Serv"},{"key":"2641_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3389\/fphar.2017.00189","volume":"8","author":"M Bujar","year":"2017","unstructured":"Bujar M, McAuslane N, Walker SR, Salek S (2017) Evaluating quality of decision-making processes in Medicines' development, regulatory review, and health technology assessment: a systematic review of the literature. Front Pharmacol 8:189. \n                    https:\/\/doi.org\/10.3389\/fphar.2017.00189","journal-title":"Front Pharmacol"},{"key":"2641_CR16","unstructured":"Williamson E, Sathe NA, Andrews JC, Krishnaswami S, McPheeters ML, Fonnesbeck C, Sanders K, Weitlauf A, Warren Z (2017) Medical Therapies for Children With Autism Spectrum Disorder\u2014An Update. Comparative Effectiveness Review No. 189. (Prepared by the Vanderbilt Evidence-based Practice Center under Contract No. 290\u20132015\u201300003-I.) AHRQ Publication No. 17-EHC009-EF. Rockville, MD: Agency for Healthcare Research and Quality"},{"key":"2641_CR17","unstructured":"Pillay J, Boylan K, Carrey N, Newton A, Vandermeer B, Nuspl M, MacGregor T, Ahmed Jafri SH, Featherstone R, Hartling L (2017) First and Second-Generation Antipsychotics in Children and Young Adults: Systematic Review Update. Comparative Effectiveness Review No. 184. (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290\u20132015\u201300001-I.) AHRQ Publication No. 17-EHC001-EF. Rockville, MD: Agency for Healthcare Research and Quality. Errata January 2018"},{"issue":"8","key":"2641_CR18","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1080\/14737175.2016.1211007","volume":"16","author":"R Rizzo","year":"2016","unstructured":"Rizzo R, Pavone P (2016) Aripiprazole for the treatment of irritability and aggression in children and adolescents affected by autism spectrum disorders. Expert Rev Neurother 16(8):867\u2013874. \n                    https:\/\/doi.org\/10.1080\/14737175.2016.1211007\n                    \n                   Review","journal-title":"Expert Rev Neurother"},{"key":"2641_CR19","doi-asserted-by":"publisher","first-page":"CD009043","DOI":"10.1002\/14651858.CD009043.pub3","volume":"6","author":"LE Hirsch","year":"2016","unstructured":"Hirsch LE, Pringsheim T (2016) Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev 6:CD009043. \n                    https:\/\/doi.org\/10.1002\/14651858.CD009043.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 2","key":"2641_CR20","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.1542\/peds.2015-2851K","volume":"137","author":"LK Fung","year":"2016","unstructured":"Fung LK, Mahajan R, Nozzolillo A, Bernal P, Krasner A, Jo B, Coury D, Whitaker A, Veenstra-Vanderweele J, Hardan AY (2016) Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and Meta-analysis. Pediatrics 137(Suppl 2):S124\u2013S135. \n                    https:\/\/doi.org\/10.1542\/peds.2015-2851K","journal-title":"Pediatrics"},{"key":"2641_CR21","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.neubiorev.2017.01.024","volume":"91","author":"C Balia","year":"2018","unstructured":"Balia C, Carucci S, Coghill D, Zuddas A (2018) The pharmacological treatment of aggression in children and adolescents with conduct disorder. Do callous-unemotional traits modulate the efficacy of medication? Neurosci Biobehav Rev 91:218\u2013238. \n                    https:\/\/doi.org\/10.1016\/j.neubiorev.2017.01.024","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"2641_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13052-017-0404-6","volume":"43","author":"S Pisano","year":"2017","unstructured":"Pisano S, Muratori P, Gorga C, Levantini V, Iuliano R, Catone G, Coppola G, Milone A, Masi G (2017) Conduct disorders and psychopathy in children and adolescents: aetiology, clinical presentation and treatment strategies of callous-unemotional traits. Ital J Pediatr 43(1):84. \n                    https:\/\/doi.org\/10.1186\/s13052-017-0404-6.","journal-title":"Ital J Pediatr"},{"issue":"2","key":"2641_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/070674371506000203","volume":"60","author":"T Pringsheim","year":"2015","unstructured":"Pringsheim T, Hirsch L, Gardner D, Gorman DA (2015) The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 2: antipsychotics and traditional mood stabilizers. Can J Psychiatr 60(2):52\u201361","journal-title":"Can J Psychiatr"},{"issue":"12","key":"2641_CR24","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1080\/17512433.2018.1549489","volume":"11","author":"G Schoretsanitis","year":"2018","unstructured":"Schoretsanitis G, Spina E, Hiemke C, de Leon J (2018) A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone. Expert Rev Clin Pharmacol 11(12):1237\u20131253. \n                    https:\/\/doi.org\/10.1080\/17512433.2018.1549489","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"2641_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40272-017-0274-9","volume":"20","author":"E Stepanova","year":"2018","unstructured":"Stepanova E, Grant B, Findling RL (2018) Asenapine treatment in pediatric patients with bipolar I disorder or schizophrenia: a review. Paediatr Drugs 20(2):121\u2013134. \n                    https:\/\/doi.org\/10.1007\/s40272-017-0274-9","journal-title":"Paediatr Drugs"},{"issue":"4","key":"2641_CR26","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1089\/cap.2017.0120","volume":"28","author":"L Xia","year":"2018","unstructured":"Xia L, Li WZ, Liu HZ, Hao R, Zhang XY (2018) Olanzapine versus risperidone in children and adolescents with psychosis: a meta-analysis of randomized controlled trials. J Child Adolesc Psychopharmacol 28(4):244\u2013251. \n                    https:\/\/doi.org\/10.1089\/cap.2017.0120","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"2641_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40263-015-0308-1","volume":"30","author":"RC Harvey","year":"2016","unstructured":"Harvey RC, James AC, Shields GE (2016) A systematic review and network meta-analysis to assess the relative efficacy of antipsychotics for the treatment of positive and negative symptoms in early-onset schizophrenia. CNS Drugs 30(1):27\u201339. \n                    https:\/\/doi.org\/10.1007\/s40263-015-0308-1","journal-title":"CNS Drugs"},{"issue":"3","key":"2641_CR28","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jaac.2016.12.013","volume":"56","author":"AK Pagsberg","year":"2017","unstructured":"Pagsberg AK, Tarp S, Glintborg D, Stenstr\u00f8m AD, Fink-Jensen A, Correll CU, Christensen R (2017) Acute antipsychotic treatment of children and adolescents with schizophrenia-spectrum disorders: a systematic review and network meta-analysis. J Am Acad Child Adolesc Psychiatry 56(3):191\u2013202. \n                    https:\/\/doi.org\/10.1016\/j.jaac.2016.12.013","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"2641_CR29","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.euroneuro.2018.03.008","volume":"28","author":"M Krause","year":"2018","unstructured":"Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Chaimani A, Leucht S (2018) Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: a network meta-analysis. Eur Neuropsychopharmacol 28(6):659\u2013674. \n                    https:\/\/doi.org\/10.1016\/j.euroneuro.2018.03.008","journal-title":"Eur Neuropsychopharmacol"},{"key":"2641_CR30","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jad.2015.11.002","volume":"191","author":"TA Ketter","year":"2016","unstructured":"Ketter TA, Miller S, Dell\u2019Osso B, Wang PW (2016) Treatment of bipolar disorder: review of evidence regarding quetiapine and lithium. J Affect Disord 191:256\u2013273. \n                    https:\/\/doi.org\/10.1016\/j.jad.2015.11.002","journal-title":"J Affect Disord"},{"key":"2641_CR31","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jad.2015.11.033","volume":"191","author":"M Meduri","year":"2016","unstructured":"Meduri M, Gregoraci G, Baglivo V, Balestrieri M, Isola M, Brambilla P (2016) A meta-analysis of efficacy and safety of aripiprazole in adult and pediatric bipolar disorder in randomized controlled trials and observational studies. J Affect Disord 191:187\u2013208. \n                    https:\/\/doi.org\/10.1016\/j.jad.2015.11.033","journal-title":"J Affect Disord"},{"issue":"6","key":"2641_CR32","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.pcl.2017.08.002","volume":"64","author":"E Stepanova","year":"2017","unstructured":"Stepanova E, Findling RL (2017) Psychopharmacology of bipolar disorders in children and adolescents. Pediatr Clin N Am 64(6):1209\u20131222. \n                    https:\/\/doi.org\/10.1016\/j.pcl.2017.08.002","journal-title":"Pediatr Clin N Am"},{"issue":"5","key":"2641_CR33","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1089\/cap.2015.0125","volume":"26","author":"Y Liu","year":"2016","unstructured":"Liu Y, Ni H, Wang C, Li L, Cheng Z, Weng Z (2016) Effectiveness and tolerability of aripiprazole in children and adolescents with Tourette\u2019s disorder: a meta-analysis. J Child Adolesc Psychopharmacol 26(5):436\u2013441. \n                    https:\/\/doi.org\/10.1089\/cap.2015.0125","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"30","key":"2641_CR34","doi-asserted-by":"publisher","first-page":"e4354","DOI":"10.1097\/MD.0000000000004354","volume":"95","author":"C Yang","year":"2016","unstructured":"Yang C, Zhang L, Zhu P, Zhu C, Guo Q (2016) The prevalence of tic disorders for children in China: a systematic review and meta-analysis. Medicine (Baltimore) 95(30):e4354. \n                    https:\/\/doi.org\/10.1097\/MD.0000000000004354","journal-title":"Medicine (Baltimore)"},{"key":"2641_CR35","doi-asserted-by":"publisher","unstructured":"Cox JH, Seri S, Cavanna AE (2016) Safety and efficacy of aripiprazole for the treatment of pediatric Tourette syndrome and other chronic tic disorders. Pediatric Health Med Ther 7:57\u201364. \n                    https:\/\/doi.org\/10.2147\/PHMT.S87121.eCollection2016.","DOI":"10.2147\/PHMT.S87121.eCollection2016."},{"key":"2641_CR36","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12888-015-0504-z","volume":"15","author":"CS Yang","year":"2015","unstructured":"Yang CS, Huang H, Zhang LL, Zhu CR, Guo Q (2015) Aripiprazole for the treatment of tic disorders in children: a systematic review and meta-analysis. BMC Psychiatry 15:179. \n                    https:\/\/doi.org\/10.1186\/s12888-015-0504-z","journal-title":"BMC Psychiatry"},{"issue":"3","key":"2641_CR37","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1089\/cap.2017.0079","volume":"28","author":"X Zhu","year":"2018","unstructured":"Zhu X, Hu J, Sun B, Deng S, Wen Y, Chen W, Qiu C, Shang D, Zhang M (2018) Comparison of unlicensed and off-label use of antipsychotics prescribed to Child and adolescent psychiatric outpatients for treatment of mental and behavioral disorders with different guidelines: the China Food and Drug Administration versus the FDA. J Child Adolesc Psychopharmacol 28(3):216\u2013224. \n                    https:\/\/doi.org\/10.1089\/cap.2017.0079","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2641_CR38","unstructured":"EMA. \n                    http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000471\/human_med_000619.jsp&mid=WC0b01ac058001d124\n                    \n                   (Access 26 Sept 2018)."},{"key":"2641_CR39","unstructured":"EMA. SPC Abilify. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000471\/WC500020170.pdf\n                    \n                   (Access 26 Sept 2018)."},{"issue":"3","key":"2641_CR40","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00787-015-0726-0","volume":"25","author":"D Piovani","year":"2016","unstructured":"Piovani D, Clavenna A, Cartabia M, Bonati M (2016) Psychotropic medicine prescriptions in Italian youths: a multiregional study. Eur Child Adolesc Psychiatry 25(3):235\u2013245. \n                    https:\/\/doi.org\/10.1007\/s00787-015-0726-0","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"9","key":"2641_CR41","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/adc.2009.179549","volume":"95","author":"F Fortinguerra","year":"2010","unstructured":"Fortinguerra F, Maschi S, Clavenna A, Bonati M (2010) Pain management in the pediatric population: the regulatory situation in Europe. Arch Dis Child 95(9):749\u2013753. \n                    https:\/\/doi.org\/10.1136\/adc.2009.179549","journal-title":"Arch Dis Child"},{"issue":"3","key":"2641_CR42","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1176\/ps.2010.61.3.325","volume":"61","author":"P Pathak","year":"2010","unstructured":"Pathak P, West D, Martin BC (2010) Weighing the evidence for pediatric antipsychotic use. Psychiatr Serv 61(3):325. \n                    https:\/\/doi.org\/10.1176\/ps.2010.61.3.325).","journal-title":"Psychiatr Serv"},{"issue":"5","key":"2641_CR43","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1177\/0269881116636107","volume":"30","author":"AN Sharma","year":"2016","unstructured":"Sharma AN, Arango C, Coghill D, Gringras P, Nutt DJ, Pratt P, Young AH, Hollis C (2016) BAP position statement: off-label prescribing of psychotropic medication to children and adolescents. J Psychopharmacol 30(5):416\u2013421. \n                    https:\/\/doi.org\/10.1177\/0269881116636107","journal-title":"J Psychopharmacol"},{"issue":"1","key":"2641_CR44","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00228-011-1097-1","volume":"68","author":"J Mason","year":"2012","unstructured":"Mason J, Pirmohamed M, Nunn T (2012) Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature. Eur J Clin Pharmacol 68(1):21\u201328. \n                    https:\/\/doi.org\/10.1007\/s00228-011-1097-1","journal-title":"Eur J Clin Pharmacol"},{"issue":"7433","key":"2641_CR45","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1136\/bmj.328.7433.227-a","volume":"328","author":"M Bonati","year":"2004","unstructured":"Bonati M, Pandolfini C (2004) Children need international formulary to guarantee rational use of drugs. BMJ 328(7433):227","journal-title":"BMJ"},{"issue":"10","key":"2641_CR46","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1176\/ajp.141.10.1195","volume":"141","author":"LT Anderson","year":"1984","unstructured":"Anderson LT, Campbell M, Grega DM, Perry R, Small AM, Green WH (1984) Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 141(10):1195\u20131202","journal-title":"Am J Psychiatry"},{"issue":"2","key":"2641_CR47","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/BF02211843","volume":"19","author":"LT Anderson","year":"1989","unstructured":"Anderson LT, Campbell M, Adams P, Small AM, Perry R, Shell J (1989) The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 19(2):227\u2013239","journal-title":"J Autism Dev Disord"},{"issue":"2","key":"2641_CR48","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/BF01531306","volume":"12","author":"M Campbell","year":"1982","unstructured":"Campbell M, Anderson LT, Small AM, Perry R, Green WH, Caplan R (1982) The effects of haloperidol on learning and behavior in autistic children. J Autism Dev Disord 12(2):167\u2013175","journal-title":"J Autism Dev Disord"},{"issue":"1","key":"2641_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00787-007-0620-5","volume":"17","author":"S Miral","year":"2008","unstructured":"Miral S, Gencer O, Inal-Emiroglu FN, Baykara B, Baykara A, Dirik E (2008) Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial. Eur Child Adolesc Psychiatry 17(1):1\u20138. \n                    https:\/\/doi.org\/10.1007\/s00787-007-0620-5","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"2641_CR50","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2147\/TCRM.S117321","volume":"13","author":"M Solmi","year":"2017","unstructured":"Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, Stubbs B, Monaco F, Vieta E, Seeman MV, Correll CU, Carvalho AF (2017) Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag 13:757\u2013777. \n                    https:\/\/doi.org\/10.2147\/TCRM.S117321","journal-title":"Ther Clin Risk Manag"},{"issue":"8","key":"2641_CR51","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00787-017-1028-5","volume":"26","author":"V Roessner","year":"2017","unstructured":"Roessner V, Wolff N, Ehrlich S, Waltereit R (2017) Need for a more developmental perspective: QTc prolongation under psychotropic medication. Eur Child Adolesc Psychiatry 26(8):871\u2013873. \n                    https:\/\/doi.org\/10.1007\/s00787-017-1028-5","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"9896","key":"2641_CR52","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0140-6736(13)61032-6","volume":"382","author":"CU Correll","year":"2013","unstructured":"Correll CU, De Hert M (2013) Antipsychotics for acute schizophrenia: making choices. Lancet 382(9896):919\u2013920. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(13)61032-6","journal-title":"Lancet"},{"key":"2641_CR53","doi-asserted-by":"publisher","unstructured":"Salarvand S, Hemati S, Adibi P, Taleghani F (2018) The quality of guidelines in non-pharmacological prevention and management of chemotherapy-induced neuropathy: a review. Oncol Rev 12(2):359. \n                    https:\/\/doi.org\/10.4081\/oncol.2018.359.eCollection2018Jul4.","DOI":"10.4081\/oncol.2018.359.eCollection2018Jul4."},{"issue":"3","key":"2641_CR54","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/bcp.12280","volume":"79","author":"W Lenney","year":"2015","unstructured":"Lenney W (2015) The development of a national children's formulary. Br J Clin Pharmacol 79(3):441\u2013445. \n                    https:\/\/doi.org\/10.1111\/bcp.12280","journal-title":"Br J Clin Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-019-02641-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02641-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02641-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T19:11:02Z","timestamp":1581016262000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-019-02641-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,7]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["2641"],"URL":"https:\/\/doi.org\/10.1007\/s00228-019-02641-0","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,7]]},"assertion":[{"value":"28 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}